

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

213051Orig1s000

STATISTICAL REVIEW(S)



U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Translational Sciences
Office of Biostatistics

STATISTICAL REVIEW AND EVALUATION

CLINICAL STUDIES

NDA/BLA: NDA 213051

Sequence #: 0001

Drug Name: Semaglutide

Indication(s): Type 2 Diabetes Mellitus (T2DM)

Applicant: Novo Nordisk

Date(s): Received: March 20, 2019
Primary Review: August 15, 2019
PDUFA Due Date: September 20, 2019

Review Priority: Expedited

Biometrics Division: Division of Biometrics II

Statistical Reviewer: Robert Abugov, Ph.D.

Concurring Reviewers: Yun Wang, Ph.D. (Team Leader)
Mark Rothmann, Ph.D. (Acting Division Director)

Medical Division: Division of Metabolism and Endocrinology Products

Clinical Team: Andrea Lungu, M.D. (Medical Officer)
Mitra Rauschecker, M.D. (Acting Team Leader)
Lisa Yanoff, M.D., Ph.D. (Acting Division Director)

Project Manager: Peter Franks

Keywords: NDA Review, Clinical Studies

Contents

1	EXECUTIVE SUMMARY	5
2	INTRODUCTION.....	6
2.1	OVERVIEW	6
2.1.1	<i>Drug Class and Indication.....</i>	<i>6</i>
2.1.2	<i>History of Drug Development.....</i>	<i>6</i>
2.1.3	<i>Data Sources.....</i>	<i>6</i>
3	STATISTICAL EVALUATION.....	7
3.1	DATA AND ANALYSIS QUALITY	7
3.2	EVALUATION OF EFFICACY.....	7
3.2.1	<i>Study Design and Endpoints</i>	<i>7</i>
3.2.2	<i>Statistical Methodologies.....</i>	<i>10</i>
3.2.3	<i>Patient Disposition, Demographic and Baseline Characteristics</i>	<i>14</i>
3.2.4	<i>Results and Conclusions</i>	<i>20</i>
3.2.4.1	<i>Primary Endpoint: Week 26 Change from Baseline Percent HbA1c.....</i>	<i>20</i>
3.2.4.2	<i>Key Secondary Endpoint: Week 26 Change from Baseline Body Weight</i>	<i>21</i>
3.2.4.3	<i>Supportive Endpoint: Week 26 Percent HbA1c Less Than 7%.....</i>	<i>23</i>
3.2.4.4	<i>Supportive Endpoint: Week 26 Change from Baseline Fasting Blood Glucose</i>	<i>25</i>
3.2.4.5	<i>Efficacy Summary</i>	<i>25</i>
3.3	EVALUATION OF SAFETY	27
4	FINDINGS IN SPECIAL/SUBGROUP POPULATIONS.....	30
5	SUMMARY AND CONCLUSIONS	42
5.1	STATISTICAL ISSUES	42
5.2	COLLECTIVE EVIDENCE	42
5.3	CONCLUSIONS AND RECOMMENDATIONS	43
5.4	LABELING RECOMMENDATIONS	44
6	APPENDIX: SHRINKAGE ESTIMATES FOR SUBGROUP ANALYSES.....	45

List of Tables

Table 1. Randomized Confirmatory Trials Reviewed for Effectiveness	7
Table 2. Randomized Confirmatory Trials Omitted from Efficacy Review	8
Table 3. Criteria for Provision of Rescue Medications.....	9
Table 4. ANCOVA Statistical Models for Primary and Secondary Endpoints	10
Table 5. Patient Disposition at Week 26, Placebo Controlled Studies 4233 and 4224	14
Table 6. Patient Disposition at Week 26, Active Controlled Studies 4222 and 4223	15
Table 7. Patient Disposition at Week 26, Placebo Controlled Studies 4234 and 4280	16
Table 8. Patient Demographics, Placebo Controlled Studies 4233 and 4224, Full Analysis Set .	17
Table 9. Patient Demographics, Active Controlled Studies 4222 and 4223, Full Analysis Set ...	18
Table 10. Patient Demographics, Placebo Controlled Studies 4234 and 4280, Full Analysis Set	19
Table 11. Change from Baseline Percent HbA1c Compared to Placebo, Week 26	20
Table 12. Change from Baseline Percent HbA1c Compared to Active Controls, Week 26.....	21
Table 13. Change from Baseline Body Weight Compared to Placebo, Week 26. (Measurement is in kilograms)	22
Table 14. Change from Baseline Body Weight Compared to Active Controls, Week 26. (Measurement is in kilograms).....	22
Table 15. Raw Proportion of HbA1c < 7%, Week 26	23
Table 16. Adjusted Proportion of HbA1c < 7% Compared to Placebo, Week 26.....	24
Table 17. Adjusted Proportion of HbA1c < 7% Compared to Active Controls, Week 26.....	25
Table 18. Change from Baseline Fasting Plasma Glucose Compared to Placebo, Week 26	26
Table 19. Change from Baseline Fasting Plasma Glucose Compared to Active Controls, Week 26	26
Table 20. Hypoglycemia Percent Incidence While on Randomized Treatment	27
Table 21. Hypoglycemia Event Rate While on Randomized Treatment.....	29
Table 22. Sample Sizes for Subgroup Analyses on Change from Baseline HbA1c.....	39
Table 23. Sample Sizes for Subgroup Analyses on Change from Baseline HbA1c, Total for Placebo-controlled Studies 4224, 42333, 4234, and 4280	42

List of Figures

Figure 1. Control of Type 1 Error, Trial 4222	12
Figure 2. Control of Type 1 Error, Trial 4223	12
Figure 3. Control of Type 1 Error, Study 4224.....	13
Figure 4. Control of Type 1 Error, Trials 4233 and 4280.....	13
Figure 5. Subgroup Analyses, Semaglutide 14 mg vs Sitagliptin, Study 4222	32
Figure 6. Subgroup Analyses, Semaglutide 14 mg vs Empagliflozin, Study 4223	33
Figure 7. Subgroup Analyses, Semaglutide 14 mg vs Placebo, Study 4224	34
Figure 8. Subgroup Analyses, Semaglutide 14 mg vs Placebo, Study 4233	35
Figure 9. Subgroup Analyses, Semaglutide 14 mg vs Placebo, Study 4234	36
Figure 10. Subgroup Analyses, Semaglutide 14 mg vs Placebo, Study 4280	37
Figure 11. Subgroup Meta-analyses, Semaglutide 14 mg vs Placebo, Studies 4224, 4234, 4233, and 4280	38

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.